The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Serial Measurement of Growth-Differentiation Factor-15 in Heart Failure: Relation to Disease Severity and Prognosis in the Valsartan Heart Failure Trial
Abstract
Background—: Growth-differentiation factor-15 (GDF-15) is emerging as a prognostic biomarker in patients with coronary artery disease. Little is known about GDF-15 as a biomarker in patients with heart failure. Methods and Results—: The circulating concentration of GDF-15 was measured at baseline (n=1734) and at 12 months (n=1517) in patients randomized in the Valsartan Heart Failure Trial (Val-HeFT). GDF-15 levels at baseline ranged from 259 to 25 637 ng/L and were abnormally high (>1200 ng/L) in 85% of patients. Higher levels were associated with features of worse heart failure and biomarkers of neurohormonal activation, inflammation, myocyte injury, and renal dysfunction. Baseline GDF-15 levels (per 100 ng/L) were associated with the risks of mortality (hazard ratio, 1.017; 95% confidence interval, 1.014 to 1.019; P <0.001) and first morbid event (hazard ratio, 1.020; 95% confidence interval, 1.017 to 1.023; P <0.001). In a comprehensive multiple-variable Cox regression model that included clinical prognostic variables, B-type natriuretic peptide, high-sensitivity C-reactive protein, and high-sensitivity troponin T, GDF-15 remained independently associated with mortality (hazard ratio, 1.007; 95% confidence interval, 1.001 to 1.014; P =0.02) but not first morbid event. At 12 months, the GDF-15 levels had increased by a similar amount in the placebo and valsartan groups ( P =0.94). Increases in GDF-15 over 12 months were independently associated with the risks of future mortality and first morbid event also after adjustment for clinical prognostic variables, B-type natriuretic peptide, high-sensitivity C-reactive protein, and high-sensitivity troponin T and their changes. Conclusions—: GDF-15 reflects information from several pathological pathways and provides independent prognostic information in heart failure. GDF-15 levels increase over time, suggesting that GDF-15 reflects a pathophysiological axis that is not completely addressed by the therapies prescribed in Val-HeFT.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DeLong, E. R., DeLong, D. M., & Clarke-Pearson, D. L. (1988) · Biometrics · doi:10.2307/2531595 · Cited by 22,649
Pencina, M. J., D' Agostino, R. B., D' Agostino, R. B., & Vasan, R. S. (2008) · Statistics in Medicine · doi:10.1002/sim.2929 · Cited by 6,493
A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
Cohn, J. N., & Tognoni, G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010713 · Cited by 3,108
Self-citationThe Seattle Heart Failure Model: Prediction of Survival in Heart Failure
Levy, W. C., Mozaffarian, D., Linker, D. T., Sutradhar, S. C., Anker, S. D., Cropp, A. B., Anand, I., Maggioni, A., Burton, P., Sullivan, M. D., et al. (2006) · Circulation · doi:10.1161/circulationaha.105.584102 · Cited by 2,021
Self-citationBraunwald, E. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0800239 · Cited by 1,257
MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-β superfamily
Bootcov, M. R., Bauskin, A. R., Valenzuela, S. M., Moore, A. G., Bansal, M., He, X. Y., Zhang, H. P., Donnellan, M., Mahler, S., Pryor, K., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.21.11514 · Cited by 1,177
B-type natriuretic peptide in cardiovascular disease
de Lemos, J. A., McGuire, D. K., & Drazner, M. H. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13976-1 · Cited by 1,067
Predictors of mortality and morbidity in patients with chronic heart failure
Pocock, S. J., Wang, D., Pfeffer, M. A., Yusuf, S., McMurray, J. J. V., Swedberg, K. B., Östergren, J., Michelson, E. L., Pieper, K. S., & Granger, C. B. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehi555 · Cited by 973
Anand, I. S., Fisher, L. D., Chiang, Y.-T., Latini, R., Masson, S., Maggioni, A. P., Glazer, R. D., Tognoni, G., & Cohn, J. N. (2003) · Circulation · doi:10.1161/01.cir.0000054164.99881.00 · Cited by 864
Self-citationMcMurray, J. J., & Pfeffer, M. A. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66621-4 · Cited by 831
Cited by
Growth Differentiation Factor 15 as a Biomarker in Cardiovascular Disease
Wollert, K. C., Kempf, T., & Wallentin, L. (2017) · Clinical Chemistry · doi:10.1373/clinchem.2016.255174 · Cited by 559
Self-citationBiomarkers for the diagnosis and management of heart failure
Castiglione, V., Aimo, A., Vergaro, G., Saccaro, L., Passino, C., & Emdin, M. (2022) · Heart Failure Reviews · doi:10.1007/s10741-021-10105-w · Cited by 512
Prognostic Utility of Novel Biomarkers of Cardiovascular Stress: The Framingham Heart Study
Wang, T. J., Wollert, K. C., Larson, M. G., Coglianese, E., McCabe, E. L., Cheng, S., Ho, J. E., Fradley, M. G., Ghorbani, A., Xanthakis, V., et al. (2012) · Circulation · doi:10.1161/circulationaha.112.129437 · Cited by 482
“15 are markedly elevated and correlate with both disease severity and mortality risk.(14,16) Emerging data suggest that GDF-15 concentrations may also be prognostic in unselected populations.”
BackgroundResultAdela, R., & Banerjee, S. K. (2015) · Journal of Diabetes Research · doi:10.1155/2015/490842 · Cited by 474
“Higher GDF-15 levels are associated with adverse outcomes independent of established clinical and biochemical risk factors [40, 65].”
BackgroundBiomarkers and diagnostics in heart failure
Gaggin, H. K., & Januzzi, J. L. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.12.014 · Cited by 423
Newby, L. K., Jesse, R. L., Babb, J. D., Christenson, R. H., De Fer, T. M., Diamond, G. A., Fesmire, F. M., Geraci, S. A., Gersh, B. J., Larsen, G. C., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.08.969 · Cited by 402
Established and Emerging Roles of Biomarkers in Heart Failure
Ibrahim, N. E., & Januzzi, J. L. (2018) · Circulation Research · doi:10.1161/circresaha.118.312706 · Cited by 306
Emerging Biomarkers in Heart Failure
van Kimmenade, R. R. J., & Januzzi, J. L. (2012) · Clinical Chemistry · doi:10.1373/clinchem.2011.165720 · Cited by 257
GDF15: a hormone conveying somatic distress to the brain
Lockhart, S. M., Saudek, V., & O’Rahilly, S. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnaa007 · Cited by 256
Kempf, T., Guba-Quint, A., Torgerson, J., Magnone, M. C., Haefliger, C., Bobadilla, M., & Wollert, K. C. (2012) · European Journal of Endocrinology · doi:10.1530/eje-12-0466 · Cited by 176
Self-citationVariability of biomarkers in patients with chronic heart failure and healthy controls
Meijers, W. C., van der Velde, A. R., Muller Kobold, A. C., Dijck-Brouwer, J., Wu, A. H., Jaffe, A., & de Boer, R. A. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.669 · Cited by 146
Cardiokines: recent progress in elucidating the cardiac secretome
Shimano, M., Ouchi, N., & Walsh, K. (2012) · Circulation · doi:10.1161/circulationaha.112.150656 · Cited by 116
The clinical impact of growth differentiation factor-15 in heart disease: A 2019 update
Arkoumani, M., Papadopoulou-Marketou, N., Nicolaides, N. C., Kanaka-Gantenbein, C., Tentolouris, N., & Papassotiriou, I. (2020) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2019.1678565 · Cited by 64
Association of Growth Differentiation Factor 15 with Mortality in a Prospective Hemodialysis Cohort
You, A. S., Kalantar-Zadeh, K., Lerner, L., Nakata, T., Lopez, N., Lou, L., Veliz, M., Soohoo, M., Jing, J., Zaldivar, F., et al. (2017) · Cardiorenal Medicine · doi:10.1159/000455907 · Cited by 43
The Role of GDF-15 in Heart Failure Patients With Chronic Kidney Disease
Benes, J., Kotrc, M., Wohlfahrt, P., Conrad, M. J., Franekova, J., Jabor, A., Lupinek, P., Kautzner, J., Melenovsky, V., & Jarolim, P. (2019) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2018.12.027 · Cited by 42
Metadata
- Authors
- Anand, I. S., Kempf, T., Rector, T. S., Tapken, H., Allhoff, T., Jantzen, F., Kuskowski, M., Cohn, J. N., Drexler, H., & Wollert, K. C.
- Venue
- Circulation
- Published
- 2010-10-05
- Volume
- 122
- Issue
- 14
- Pages
- 1387-1395
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2071101151
- Cited by
- 319
- References
- 38
- FWCI
- 11.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.